Interventional Psychiatry

Comprehensive assessment, consultation and treatment for complex psychiatric illnesses

Interventional Psychiatric Services (IPS) at Yale New Haven Psychiatric Hospital (YNHPH) combines clinical and research advances of the past two decades, offering hope to patients and their families. Interventional psychiatry is an emerging subspecialty that uses neuro- technologies to identify and treat brain conditions that contribute to psychiatric disorders. This is especially helpful for patients for whom traditional psychotherapies and medications have not been effective.

Consultation

We offer expert, comprehensive consultation on complex psychiatric cases. A referral from the primary psychiatric clinician is required.

IPS specializes in treatment of:

  • Depression
  • Schizophrenia
  • Refractory mania
  • Bipolar disease
  • Schizophrenic affective disorders
  • Mood disorders

IPS is part of the YNHPH and the Yale Center for Mood and Stress Disorders. The hospital offers both inpatient and outpatient services for adolescent, adult and geriatric patients.

Electroconvulsive Therapy (ECT)

YNHPH offers electroconvulsive therapy (ECT) for patients diagnosed with severe depression and certain other mental disorders, including bipolar disorder or schizoaffective disorder. Available on both an inpatient and outpatient basis, ECT is a safe and effective treatment. ECT is administered by our team of specially trained psychiatrists, registered nurses and anesthesiologists, following the standards of Electroconvulsive Therapy Practice developed by the American Psychiatric Association.

Esketamine and Ketamine Infusion Therapy (KIT)

The Yale Department of Psychiatry has been at the forefront of research into the use of brain stimulation therapy to treat disorders like depression, schizophrenia, and bipolar disease. In the late-1990s, Yale researchers were the first to discover that the drug ketamine, which is primarily used to induce and maintain anesthesia, provided rapid relief to some chronically depressed patients who did not respond to traditional medication. In March 2019, Esketamine (Spravato) was approved by the US Food and Drug Administration (FDA) for the treatment of depression and YNHPH is one of the few sites in Connecticut that offers this treatment.

If considered an appropriate treatment option after a thorough evaluation process, IPS offers Esketamine and ketamine treatments in a safe, monitored environment administered by highly experienced physicians.

Transcranial Magnetic Stimulation (TMS)

YNHPH also offers Transcranial Magnetic Stimulation (TMS), which is used for patients with serious depressive disorders who have not improved with various antidepressants. It does not require hospitalization, anesthesia or a drug regime, but uses brief magnetic fields, not unlike those used in diagnostic magnetic resonance imaging (MRI).

Clinical Trials and Referrals

IPS also works closely with the Yale Depression Research Program to offer opportunities to participate in cutting-edge clinical trials with novel antidepressant medications and innovative treatments when appropriate.

A referral from a physician or nurse practitioner is required and the patient must undergo an evaluation by a Yale Interventional Psychiatry psychiatrist before a treatment plan is developed. IPS staff will work collaboratively with the referring provider.

Most treatments through IPS are reimbursed by Medicare, Medicaid and/or covered by commercial insurances.

For more information, or to make a referral, call 844-228-5078